國家衛生研究院 NHRI:Item 3990099045/9730
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 910730      在线人数 : 884
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/9730


    题名: Antivascular activities of novel tubulin binding agent BPR0L075
    作者: Liu, XL;Liu, L;Beck, H;Hsieh, HP;Boreddy, S;Srivastava, S;Mason, RP
    贡献者: Institute of Biotechnology and Pharmaceutical Research
    摘要: BPR0L075, 6-methoxy-3-(3′,4′,5′-trimethoxy-benzoyl)-1H-indole, is a novel tubulin binding agent that inhibits tubulin polymerization through binding to the colchicine binding site. We evaluated the antiangiogenic and antivascular properties of BPR0L075 in vitro and in vivo. Human umbilical vein endothelial cells (HUVEC) were treated with BPR0L075, and effects on endothelial cell morphology, migration, and inhibition of tube formation on extracellular matrix were determined in vitro. The BPR0L075 induced inhibition of neovasculature formation was evaluated by rat aortic ring ex vivo assay. Using a validated dynamic bioluminescence imaging method, we assessed acute vascular disrupting effects of BPR0L075 on luciferase-expressing MCF7 human breast mammary fat pad xenografts. The disruption of tumor vascular perfusion after BPR0L075 treatment was confirmed using the perfusion marker Hoechst 33342 and CD31 staining by fluorescence microscopy. Exposure of BPR0L075 (10 nM) inhibits the endothelial cell migration (within 24 hr) and tube formation on Matrigel (3-6 hr). BPR0L075 treatment also blocked angiogenesis in rat aortic ring assay. A single dose of BPR0L075 induced rapid temporary tumor vascular shutdown evidenced by rapid and reproducible decrease of light emission from luciferase-expressing breast tumors. Histological staining using Hoechst dye and anti-CD31 antibody revealed a time-dependent reduction of tumor perfusion after 2, 4, and 24h of BPR0L075 treatment. Taken together, our results show that the novel tubulin-binding agent BPR0L075 alters endothelial cell tubule formation, prevents cell migration, and inhibits the formation of neovessels. These properties of BPR0L075 may ultimately contribute to the loss of tumor blood vessel integrity causing rapid tumor vascular shutdown in experimental breast tumors.
    日期: 2011-04
    關聯: Cancer Research. 2011 Apr;71:Abstract number 5309.
    Link to: http://dx.doi.org/10.1158/1538-7445.am2011-5309
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0008-5472&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000209701301174
    显示于类别:[謝興邦] 會議論文/會議摘要

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI000209701301174.pdf25KbAdobe PDF258检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈